Dr. Leah Backhus discusses how the minimally invasive chemotherapy technique offers a new option for pleural mesothelioma patients who aren't candidates for more extensive surgery. CHESTNUT HILL, MA / ...

DETAILS ON THE HIPEC PROCEDURE. PAM PHILLIPS IS GRATEFUL FOR EVERY MINUTE IN 2020 FOR 11 NEWS FIRST CAUGHT UP WITH HER NINE YEARS AGO WHEN SHE WAS A NEW CANCER SURVIVOR IN 2009, SHE WAS DIAGNOSED WITH ...

Brain cancers are notoriously difficult to treat because most chemotherapy drugs can't breach the blood-brain barrier, a microscopic layer of cells that protect the brain from toxins. But researchers ...

· First in-human trial used a novel ultrasound device to temporarily open the blood-brain barrier to deliver chemotherapy · Procedure led to a four- to six-fold increase in drug concentrations in the ...

When Kate Middleton, the princess of Wales, announced in March 2024 that she was receiving "preventive chemotherapy" following abdominal surgery, many wondered what that entails. Formally known as ...

A type of chemotherapy drug, called mitoxantrone, can potentially treat multiple sclerosis (MS) by suppressing blood cells that attack your myelin, the protective layer covering your brain and spinal ...

A unique cancer treatment — known as HIPEC surgery — is going places that traditional chemotherapy treatments cannot — directly inside the abdomen to the tumor. This highly advanced, two-phase surgery ...

Patients with radiologically staged T3-4, N0-2, M0 colon cancer were randomly allocated (2:1) to 6 weeks oxaliplatin-fluoropyrimidine preoperatively plus 18 postoperatively (NAC group) or 24 weeks ...

Intraperitoneal (IP) chemotherapy is a type of ovarian cancer treatment in which chemo drugs are directly pumped into your belly cavity (also called peritoneal cavity). When you get chemo this way, it ...

When chemotherapy drugs accidentally leak into the tissues surrounding your veins or catheter, it’s called extravasation. While it doesn’t happen very often, it’s a serious complication. Chemotherapy ...

The SUBITO trial, presented by Rianne L Seefat and colleagues in The Lancet Oncology,1 revisits the long-standing debate ...